Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration

David R. Gandara, Fausto Roila, David Warr, Martin J. Edelman, Edith A. Perez, Richard J. Gralla

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Selective antagonists to the Type 3 serotonin receptor (5HT3) in combination with corticosteroids are now considered the standard of care for the prevention of emesis from moderately to highly emetogenic chemotherapy. Here we address issues of optimal dose, schedule and route of administration of four currently available selectable 5HT3 antagonists. This paper utilizes an evidence based medicine approach to the literature regarding this class of drugs, emphasizing the results large, randomized, controlled trials to make formal recommendations concerning optimal use of this important new class of anti-emetic agents. We conclude that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome. Furthermore, a single dose is as effective as multiple doses or continuous infusion, and finally, emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalSupportive Care in Cancer
Volume6
Issue number3
DOIs
StatePublished - May 1998
Externally publishedYes

Fingerprint

Vomiting
Appointments and Schedules
Emetics
Receptors, Serotonin, 5-HT3
Drug Therapy
Antiemetics
Evidence-Based Medicine
Standard of Care
Pharmaceutical Preparations
Intravenous Administration
Adrenal Cortex Hormones
Randomized Controlled Trials
Therapeutics

Keywords

  • Chemotherapy induced emesis
  • Dolesetron
  • Granisetron
  • Ondansetron
  • Serotonin receptors
  • Tropisetron

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. / Gandara, David R.; Roila, Fausto; Warr, David; Edelman, Martin J.; Perez, Edith A.; Gralla, Richard J.

In: Supportive Care in Cancer, Vol. 6, No. 3, 05.1998, p. 237-243.

Research output: Contribution to journalArticle

@article{25c2ba52eaf64b81b5f3e3fce923ecca,
title = "Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration",
abstract = "Selective antagonists to the Type 3 serotonin receptor (5HT3) in combination with corticosteroids are now considered the standard of care for the prevention of emesis from moderately to highly emetogenic chemotherapy. Here we address issues of optimal dose, schedule and route of administration of four currently available selectable 5HT3 antagonists. This paper utilizes an evidence based medicine approach to the literature regarding this class of drugs, emphasizing the results large, randomized, controlled trials to make formal recommendations concerning optimal use of this important new class of anti-emetic agents. We conclude that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome. Furthermore, a single dose is as effective as multiple doses or continuous infusion, and finally, emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.",
keywords = "Chemotherapy induced emesis, Dolesetron, Granisetron, Ondansetron, Serotonin receptors, Tropisetron",
author = "Gandara, {David R.} and Fausto Roila and David Warr and Edelman, {Martin J.} and Perez, {Edith A.} and Gralla, {Richard J.}",
year = "1998",
month = "5",
doi = "10.1007/s005200050160",
language = "English (US)",
volume = "6",
pages = "237--243",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration

AU - Gandara, David R.

AU - Roila, Fausto

AU - Warr, David

AU - Edelman, Martin J.

AU - Perez, Edith A.

AU - Gralla, Richard J.

PY - 1998/5

Y1 - 1998/5

N2 - Selective antagonists to the Type 3 serotonin receptor (5HT3) in combination with corticosteroids are now considered the standard of care for the prevention of emesis from moderately to highly emetogenic chemotherapy. Here we address issues of optimal dose, schedule and route of administration of four currently available selectable 5HT3 antagonists. This paper utilizes an evidence based medicine approach to the literature regarding this class of drugs, emphasizing the results large, randomized, controlled trials to make formal recommendations concerning optimal use of this important new class of anti-emetic agents. We conclude that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome. Furthermore, a single dose is as effective as multiple doses or continuous infusion, and finally, emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.

AB - Selective antagonists to the Type 3 serotonin receptor (5HT3) in combination with corticosteroids are now considered the standard of care for the prevention of emesis from moderately to highly emetogenic chemotherapy. Here we address issues of optimal dose, schedule and route of administration of four currently available selectable 5HT3 antagonists. This paper utilizes an evidence based medicine approach to the literature regarding this class of drugs, emphasizing the results large, randomized, controlled trials to make formal recommendations concerning optimal use of this important new class of anti-emetic agents. We conclude that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome. Furthermore, a single dose is as effective as multiple doses or continuous infusion, and finally, emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.

KW - Chemotherapy induced emesis

KW - Dolesetron

KW - Granisetron

KW - Ondansetron

KW - Serotonin receptors

KW - Tropisetron

UR - http://www.scopus.com/inward/record.url?scp=0031596456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031596456&partnerID=8YFLogxK

U2 - 10.1007/s005200050160

DO - 10.1007/s005200050160

M3 - Article

VL - 6

SP - 237

EP - 243

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -